Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Eli Lilly

Drugmaker Eli Lilly convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical that found Lilly's migraine drug Emgality infringed three patents related to Teva's rival drug Ajovy.

US judge overturns Eli Lilly's $176.5 million loss in Teva patent case

Teva Pharmaceutical Industries has faced significant challenges and a decline in shareholder value over the past decade. The company has resolved its opioid litigation with U.S. states and is focusing on maximizing growth in innovative products and becoming a generics powerhouse. Teva's strategic shift and efficient capital allocation position it for potential recovery and success, although it still faces risks and must execute its strategy effectively.

Teva: Focus On Innovation And Growth Means The Times They Are A Changing

Every week, I am invited on Business First AM with Angela Miles to discuss the market and give a stock pick. This week, I covered TEVA, a stock I have talked about a few times and one, full disclosure, we are positioned in.

TEVA: A Pharmaceutical Stock to Watch Right Now

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Morgan Stanley 21st Annual Global Healthcare Conference 2023 Call September 11, 2023 8:40 AM ET Company Participants Richard Francis - Chief Executive Officer Conference Call Participants Thibault Boutherin - Morgan Stanely Thibault Boutherin So, good morning, everyone. Thank you for joining this session of the Morgan Stanley Global Healthcare Conference.

Teva Pharmaceutical Industries Limited (TEVA) Morgan Stanley 21st Annual Global Healthcare Conference 2023 (Transcript)

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Morgan Stanley Global Healthcare Conference on Monday, September 11, 2023. The presentation will begin at 8:40 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version of the webcast will be available.

Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 16 data presentations across its neuroscience portfolio happening at Psych Congress on September 6-10 in Nashville, TN. Abstracts include data for AUSTEDO, once-daily AUSTEDO XR, UZEDY, TV-44749 and AJOVY. Once-daily AUSTEDO XR, a new formulation of twice-daily AUSTEDO was approved by the U.S. Food and Drug administration (FDA.

Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023

Alkermes

Shares of Alkermes PLC ALKS, +9.68% jumped 10% Wednesday after the Dublin-based biopharma company announced a settlement of patent litigation with Teva Pharmaceuticals USA Inc. TEVA, relating to Vivitrol, a treatment for alcohol and opioid dependence. The settlement agreement, which will be submitted for regulatory review, gives Teva a license to market a generic version of Vivitrol in the U.S. starting in early 2027, Alkermes said in a release.

Alkermes shares surge after settlement with Teva on alcohol dependence treatment

On August 2, Teva Pharmaceutical published its financial report for the second quarter of 2023, which showed an improvement in its financial position. Teva Pharmaceutical's revenue for the second quarter of 2023 was $3.88 billion, up 6% from the previous quarter and up 2.4% from the second quarter of 2022. TEV-48574 is a key gem in the company's portfolio, which is being developed for treating inflammatory bowel disease and continues to demonstrate excellent efficacy in vitro studies.

The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider

TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.

TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)

TEVA to Pay $250 Million to Settle Price-Fixing Charges

Generic drug maker Teva Pharmaceuticals is to pay US $225 million in fines after admitting price-fixing on a range of drugs in the US. Teva and another firm it worked with, Glenmark Pharmaceuticals, have received deferred prosecution agreements, so as to avoid a trial or criminal prosecution.

Teva Pharma lands US$225 million fine for price-fixing

Activision Blizzard

Microsoft

Zoom Video

Fabrinet

Nordson

Activision Blizzard shares ATVI, +0.28% rose 1% after Microsoft reached a deal with Ubisoft Entertainment to license the cloud streaming rights to Activision games, in an attempt to secure approval from the U.K. competition regulator. Microsoft stock MSFT, +1.71% also rose in premarket trade.

Zoom Video stock climbs after earnings, Activision Blizzard advances on Microsoft pact and other stocks on the move

The generic drugmaker's U.S. unit also must sell the drug line for cholesterol treatment pravastatin.

Teva Agrees to Pay $225 Million to Settle U.S. Price-Fixing Charges

Teva Pharmaceuticals agreed to pay more than $200 million in fines and divest a key generic drug treating cholestoral to settle price-fixing charges from the US Department of Justice, the agency announced Monday.

Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. TEVA, +0.52%, said Monday that it has reached an agreement with the U.S. Department of Justice to settle criminal price-fixing charges brought against the company in 2020.

Teva Pharmaceuticals agrees to pay $225 million fine to settle price-fixing charges

It's the latest resolution in a string of cases related to price-fixing, referring to competitors banding together to artificially set the price of a product.

Teva to pay $225 million in fines and divest generic drug to resolve price-fixing charges

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached a deferred prosecution agreement (DPA) with the U.S. Department of Justice (DOJ) to settle the criminal price-fixing charges brought against Teva in 2020. Under the DPA, which will allow Teva to avoid mandatory exclusion from participation in U.S. federal health care programs, Teva will pay a fine of $225 million over five years,.

Teva Settles Price Fixing Charges With U.S. DOJ

Teva Pharmaceutical Industries Ltd has agreed to pay up to $126 million to U.S. hospitals over 18 years to settle claims that its marketing of opioid drugs raised the hospitals' operating costs.

Teva agrees to pay $126 mln to US hospitals over opioids

TEVA's second-quarter results were strong as it beat estimates for earnings as well sales.

TEVA Q2 Earnings & Sales Top as Austedo Outperforms, Stock Up

MONTPELLIER, France--(BUSINESS WIRE)--MedinCell (Paris:MEDCL): Access here the complete press release During today's Q2 earnings call, Richard Francis, President and CEO of Teva, and Eric Hughes, Executive Vice President, Global R&D & Chief Medical Officer, commented the US launch of UZEDY since May 2023 and the olanzapine Long-Acting Injectable (LAI). About UZEDY Richard Francis said1: “We are actually right on plan or slightly ahead of our market access strategy targets and we are ver.

MedinCell's Partner Teva Announces Successful Launch of UZEDY™

Teva Pharmaceutical Industries , will still pursue launching a biosimilar for arthritis drug Humira next year despite a crowded marketplace, chief executive Richard Francis said on Wednesday.

Teva Pharm CEO: Not too late to launch Humira biosimilar in 2024

The headline numbers for Teva Pharmaceutical Industries Ltd. (TEVA) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries Ltd. (TEVA) Q2 Earnings

Teva stock took a run at its 200-day moving average early Wednesday after the generic drugs giant beat second-quarter estimates.

Teva Takes A Run At Its 200-Day Line After Second-Quarter Beat And Raise

Teva Pharmaceutical Industries reported higher than expected second-quarter profit boosted by a jump in sales of its Austedo treatment for Huntington's Disease.

Teva Pharmaceutical Q2 profit tops estimates, Huntington's drug sales jump

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended June 30, 2023. Mr. Richard Francis, Teva's President and CEO, said, “Teva continued to deliver solid performance this quarter, with revenues coming in at $3.9 billion, up 4% vs. the second quarter of 2022 in local currency terms and non-GAAP gross margin up 3.1 percentage points vs. the first quarter of 2023. Our growth drivers continue to provide confidence.

News for Teva Pharmaceutical Stock (TEVA)